Allarity Therapeutics, Inc. (ALLR) — Financial statements
Income statement, balance sheet, and cash flow for Allarity Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.12↑13.2% | 0.11 | |
| Gross Profit | 0.32 | 0.00 | 0.00↑100.0% | -0.12↓13.2% | -0.11 | |
| Operating Expenses | ||||||
| R&D Expenses | 7↑8.3% | 6↓14.2% | 7↑2.5% | 7↓51.2% | 14 | |
| General & Administrative Expenses | 6↓44.7% | 11↑14.1% | 10↑0.6% | 10↓19.4% | 12 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↓44.7% | 11↑14.1% | 10↑0.6% | 10↓19.4% | 12 | |
| Other Expenses | 0.00↓100.0% | 10 | 0.00↓100.0% | 18 | 0.00 | |
| Operating Expenses | 13↓52.6% | 27↑59.0% | 17↓50.3% | 34↑29.8% | 27 | |
| Total Costs & Expenses | 13↓52.6% | 27↑59.0% | 17↓50.3% | 34↑29.8% | 27 | |
| Operating Results | ||||||
| Operating Income | -13↑53.7% | -27↓59.0% | -17↑50.3% | -34↓29.8% | -27 | |
| Depreciation & Amortization | -0.01↓244.4% | 0.01↓75.7% | 0.04↓38.3% | 0.06↓43.4% | 0.11 | |
| EBITDA | -11↑54.4% | -24↓114.8% | -11↑34.8% | -17↑32.9% | -26 | |
| EBIT | -11↑54.4% | -24↓114.2% | -11↑34.8% | -17↑32.9% | -26 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.62↑613.3% | -0.12↑74.8% | -0.48↓146.6% | -0.19↑69.8% | -0.64 | |
| Interest Income | 0.80↑50.3% | 0.53↑2322.7% | 0.02↓26.7% | 0.03 | 0.00 | |
| Interest Expense | 0.19↓71.7% | 0.65↑31.1% | 0.50↑123.3% | 0.22↓65.2% | 0.64 | |
| Non-Operating Income | -2↑48.0% | -3↑48.4% | -6↑66.0% | -17↓2412.0% | -0.68 | |
| Other Income / Expenses | 1↓41.4% | 2↓55.8% | 5↓68.5% | 17↑41080.5% | 0.04 | |
| Income Before Tax | -11↑54.9% | -25↓110.7% | -12↑32.8% | -18↑33.7% | -27 | |
| Income Tax Expense | 0.00↑100.0% | -0.38↓559.0% | 0.08↑105.5% | -2↓1243.6% | 0.13 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -11↑54.2% | -25↓106.0% | -12↑25.9% | -16↑39.7% | -27 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -11↑54.2% | -25↓106.0% | -12↑25.9% | -16↑39.7% | -27 | |
| Bottom-Line Net Income | -11↑55.4% | -25↓23.2% | -20↑3.0% | -21↑21.0% | -27 | |
| EPS (Basic) | -0.78↑95.1% | -15.79↑99.7% | -6,031.31↑81.0% | -31,799.09↑59.8% | -79,074.18 | |
| EPS (Diluted) | -0.78↑95.1% | -15.79↑99.7% | -6,031.31↑81.0% | -31,799.09↑59.8% | -79,074.18 | |
| Weighted Average Shares | 14↑794.8% | 2↓51.6% | 3↑29147.9% | 0.01↑49.8% | 0.01 | |
| Weighted Average Diluted Shares | 14↑794.8% | 2↓51.6% | 3↑29147.9% | 0.01↑49.8% | 0.01 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.